July 10, 2019
Taris bio tests its TAR-200 with Opdivo
Taris Bio has dosed the first patient in a test of its investigational product TAR-200 combined with Bristol-Myers Squibb’s Opdivo.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Bristol-Myers Squibb
June 28, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb) announced today the extension of the expiration date of the offers to…
June 24, 2019
Global Opdivo (Nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) Market Review & Forecast 2017-2026
DUBLIN–(BUSINESS WIRE)–The “Opdivo” drug pipelines has been added to ResearchAndMarkets.com’s offering. Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human…
April 25, 2019
Bristol-Myers Squibb Reports First Quarter Financial Results
Increases First Quarter Revenues 14% to $5.9 Billion Posts First Quarter GAAP EPS of $1.04 and Non-GAAP EPS of $1.10…
April 2, 2019
Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients
Analyses include the longest follow-up of lung cancer patients treated with Immuno-Oncology therapy in phase 3 randomized trials PRINCETON, N.J.–(BUSINESS…
March 29, 2019
Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene’s (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co., Ltd.…
March 19, 2019
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene
Urges Shareholders to Vote “FOR” the Proposed Transaction on the WHITE Proxy Card NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY)…
December 4, 2018
Bristol-Myers Squibb to distribute $3.8 billion of pension obligations to its US retirement income plan participants
Bristol-Myers Squibb will transfer $3.8 billion of U.S. pension obligations through a full termination of its U.S. Retirement Income Plan.…
March 2, 2018
BMS welcomes new Board member
Bristol-Myers Squibb’s Board of Directors has elected José Baselga, M.D., Ph.D., to the Board, effective March 1, 2018. Dr. Baselga will…
February 1, 2018
Mylan launches Efavirenz in USA, first generic version of BMS’s HIV type 1 treatment Sustiva
Mylan is launching Efavirenz Tablets USP, 600 mg, in the USA, the first generic version of Bristol-Myers Squibb’s Sustiva, which…